| Parameter | Compound 11 (Most active) | Hydroxyflotamide | ||
| Absorption | Result | Probability | Result | Probability |
| Blood-Brain Barrier | BBB+ | 0.8199 | BBB- | 0.8396 |
| Human Intestinal Absorption | HIA+ | 0.9623 | HIA+ | 0.9625 |
| Caco-2 Permeability | Caco2- | 0.6938 | Caco2- | 0.5898 |
| P-glycoprotein Substrate | Non-substrate | 0.5229 | Non-substrate | 0.6835 |
| P-glycoprotein Inhibitor | Non-inhibitor | 0.6193 | Non-inhibitor | 0.6634 |
| Non-inhibitor | 0.9403 | Non-inhibitor | 0.8954 | |
| Renal Organic Cation Transporter | Non-inhibitor | 0.8429 | Non-inhibitor | 0.9684 |
| Distribution Metabolism | ||||
| CYP450 2C9 Substrate | Non-substrate | 0.7697 | Non-substrate | 0.8100 |
| CYP450 2D6 Substrate | Non-substrate | 0.8041 | Non-substrate | 0.8308 |
| CYP450 3A4 Substrate | Non-substrate | 0.5490 | Substrate | 0.5225 |
| CYP450 1A2 Inhibitor | Non-inhibitor | 0.8211 | Non-inhibitor | 0.6559 |
| CYP450 2C9 Inhibitor | Non-inhibitor | 0.6976 | Inhibitor | 0.5266 |
| CYP450 2D6 Inhibitor | Non-inhibitor | 0.7479 | Non-inhibitor | 0.8475 |
| CYP450 2C19 Inhibitor | Non-inhibitor | 0.6359 | Inhibitor | 0.5260 |
| CYP450 3A4 Inhibitor | Non-inhibitor | 0.8317 | Inhibitor | 0.5374 |
| CYP Inhibitory Promiscuity | Low CYP Inhibitory Promiscuity | 0.5981 | High CYP Inhibitory Promiscuity | 0.5357 |
| Excretion Toxicity | ||||
| Human Ether-a-go-go-Related Gene Inhibition | Weak inhibitor | 0.9390 | Weak inhibitor | 0.9957 |
| AMES Toxicity | Non AMES toxic | 0.5689 | AMES toxic | 0.5150 |
| Carcinogens | Non-carcinogens | 0.6999 | Carcinogens | 0.5530 |
| Fish Toxicity | High FHMT | 0.9702 | High FHMT | 0.9984 |
| Tetrahymena Pyriformis Toxicity | High TPT | 0.8713 | High TPT | 0.9757 |
| Honey Bee Toxicity | Low HBT | 0.8241 | Low HBT | 0.8084 |
| Biodegradation | Not ready biodegradable | 0.9876 | Not ready biodegradable | 1.0000 |
| Acute Oral Toxicity | III | 0.5839 | III | 0.5581 |
| Carcinogenicity (Three-class) | Non-required | 0.5815 | Non-required | 0.4472 |